Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001659104 | SCV001875338 | uncertain significance | not provided | 2024-08-22 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis indicates that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Labcorp Genetics |
RCV001832841 | SCV002942651 | benign | Nemaline myopathy 2 | 2024-01-23 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV001659104 | SCV003811586 | uncertain significance | not provided | 2023-10-31 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003163783 | SCV003880168 | uncertain significance | Inborn genetic diseases | 2023-02-22 | criteria provided, single submitter | clinical testing | The c.2921G>A (p.R974Q) alteration is located in exon 29 (coding exon 27) of the NEB gene. This alteration results from a G to A substitution at nucleotide position 2921, causing the arginine (R) at amino acid position 974 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001832841 | SCV002077767 | uncertain significance | Nemaline myopathy 2 | 2020-01-24 | no assertion criteria provided | clinical testing |